11/23/2020 7:21:44 AM
Merck Submits Applications To FDA And EMA For Licensure Of V114
11/23/2020 7:20:20 AM
Merck To Acquire OncoImmune For An Upfront Payment Of $425 Mln
11/16/2020 7:28:42 AM
Merck Advances Phase 3 Trial To Evaluate Investigational Islatravir
11/5/2020 6:55:29 AM
VelosBio Agrees To Be Acquired By Subsidiary Of Merck For $2.75 Bln Cash
10/28/2020 8:04:58 AM
Seagen Reports Closing Of $1.0 Bln Stock Sale To Merck
10/27/2020 6:49:45 AM
Merck Q3 GAAP EPS $1.16; Non-GAAP EPS $1.74
10/21/2020 6:58:52 AM
Merck To Present Data From Infectious Diseases And Vaccines Program During IDWeek 2020
10/20/2020 6:47:18 AM
Merck Reports Positive Topline Results From Two Addl Phase 3 Adult Studies Evaluating V114
10/15/2020 7:03:02 AM
Merck: Health Canada Approves KEYTRUDA As First-line Treatment For Patients With Metastatic Recurrent HNSCC
10/14/2020 8:23:18 AM
Merck Issues 2019/2020 Corporate Responsibility Report